Evaluation of efficacy and safety of a response adapted therapy adding bortezomib in newly diagnosed, transplant ineligible multiple myeloma patients with insufficient efficacy by lenalidomide - dexamethasone (Rd) therapy.
Phase of Trial: Phase II
Latest Information Update: 06 Jun 2017
At a glance
- Drugs Bortezomib (Primary) ; Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- Acronyms W-JHS MM01
- 02 Jun 2017 Status changed from not yet recruiting to recruiting.
- 16 Mar 2017 New trial record